Teva head Schultz mixes generics with specialty
Teva is merging its generics and branded ‘specialty’ operations into a single unit with immediate effect, as part of a restructuring led by the Israeli firm’s new president and chief executive officer, Kåre Schultz. Less than a month after he took the role, Schultz said the firm was taking “decisive and immediate action to address external pressures and internal inefficiencies”, after impairment charges wiped out US$6.1 billion of goodwill earlier this year, and the company faces a high debt burden in the wake of buying Actavis.
You may also be interested in...
Stada has appointed general managers for its businesses in Germany and Poland. Meanwhile, US and UK industry associations the AAM and BGMA have announced appointments, Glenmark has added an ex-Teva executive to its board of directors and the MHRA has named a new chair.
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essexor biosimilar bevacizumab to treat ophthalmic diseases.
Dr Reddy’s says it has suffered a cyber-attack and has isolated “all data center services” so that it can take actions to mitigate the impact.